ASX - By Stock
|
SNT |
Re:
Ann: FDA Grants Orphan Drug Status for PXS Anti Fibrotic Drug
|
|
quattro1
|
30 |
8.8K |
3 |
15/07/20 |
15/07/20 |
ASX - By Stock
|
30
|
8.8K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Derisking PXS
|
|
quattro1
|
5 |
3.8K |
5 |
04/04/18 |
04/04/18 |
ASX - By Stock
|
5
|
3.8K
|
5
|
|
ASX - By Stock
|
SNT |
Is a re-rate imminent?
|
|
quattro1
|
2 |
2.0K |
7 |
12/03/18 |
12/03/18 |
ASX - By Stock
|
2
|
2.0K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
Derisking PXS
|
|
quattro1
|
5 |
3.8K |
11 |
27/01/18 |
27/01/18 |
ASX - By Stock
|
5
|
3.8K
|
11
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Boehringer Initiating Phase 2a Study Diabetic Retinopathy
|
|
quattro1
|
25 |
12K |
3 |
10/10/17 |
10/10/17 |
ASX - By Stock
|
25
|
12K
|
3
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: PROACTIVE INVESTORS EVENTS
|
|
quattro1
|
5 |
1.9K |
14 |
06/10/17 |
06/10/17 |
ASX - By Stock
|
5
|
1.9K
|
14
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Boehringer Initiating Phase 2a Study Diabetic Retinopathy
|
|
quattro1
|
25 |
12K |
7 |
26/09/17 |
26/09/17 |
ASX - By Stock
|
25
|
12K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Boehringer Initiating Phase 2a Study Diabetic Retinopathy
|
|
quattro1
|
25 |
12K |
0 |
08/09/17 |
08/09/17 |
ASX - By Stock
|
25
|
12K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Boehringer Initiating Phase 2a Study Diabetic Retinopathy
|
|
quattro1
|
25 |
12K |
7 |
08/09/17 |
08/09/17 |
ASX - By Stock
|
25
|
12K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
News: PXS Boehringer Ingelheim initiates phase IIA study of compound acquired from Pharmaxis
|
|
quattro1
|
9 |
3.6K |
3 |
25/08/17 |
25/08/17 |
ASX - By Stock
|
9
|
3.6K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Presentation by CEO at Bioshares Biotech Summit
|
|
quattro1
|
6 |
3.2K |
0 |
02/08/17 |
02/08/17 |
ASX - By Stock
|
6
|
3.2K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Presentation by CEO at Bioshares Biotech Summit
|
|
quattro1
|
6 |
3.2K |
2 |
27/07/17 |
27/07/17 |
ASX - By Stock
|
6
|
3.2K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Therapeutics GvHD Clinical Trial & Corporate Progress
|
|
quattro1
|
49 |
14K |
1 |
27/06/17 |
27/06/17 |
ASX - By Stock
|
49
|
14K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
PacificEdge update
|
|
quattro1
|
276 |
93K |
7 |
24/05/17 |
24/05/17 |
ASX - By Stock
|
276
|
93K
|
7
|
|
ASX - By Stock
|
AN1 |
Re:
PacificEdge update
|
|
quattro1
|
276 |
93K |
7 |
27/04/17 |
27/04/17 |
ASX - By Stock
|
276
|
93K
|
7
|
|
Charts
|
AN1 |
Re:
CDY Breakout
|
|
quattro1
|
27 |
11K |
11 |
04/04/17 |
04/04/17 |
Charts
|
27
|
11K
|
11
|
|
ASX - By Stock
|
SNT |
Re:
News: PXS Synairgen announces additional positive data from LOXL2 inhibitor programme
|
|
quattro1
|
18 |
9.2K |
1 |
30/03/17 |
30/03/17 |
ASX - By Stock
|
18
|
9.2K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Japanese News
|
|
quattro1
|
19 |
4.5K |
6 |
29/03/17 |
29/03/17 |
ASX - By Stock
|
19
|
4.5K
|
6
|
|
ASX - By Stock
|
AN1 |
Re:
Company Research
|
|
quattro1
|
48 |
16K |
7 |
27/03/17 |
27/03/17 |
ASX - By Stock
|
48
|
16K
|
7
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Change of Director's Interest Notice - Halasz
|
|
quattro1
|
33 |
12K |
8 |
21/03/17 |
21/03/17 |
ASX - By Stock
|
33
|
12K
|
8
|
|
ASX - By Stock
|
AN1 |
EU launch of Evolis
|
|
quattro1
|
0 |
492 |
8 |
16/03/17 |
16/03/17 |
ASX - By Stock
|
0
|
492
|
8
|
|
ASX - By Stock
|
SNT |
"Enticing target for drug acquisition and partnerships"
|
|
quattro1
|
3 |
2.2K |
12 |
17/02/17 |
17/02/17 |
ASX - By Stock
|
3
|
2.2K
|
12
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Quarterly Report to Shareholders - December 2016
|
|
quattro1
|
7 |
3.9K |
7 |
01/02/17 |
01/02/17 |
ASX - By Stock
|
7
|
3.9K
|
7
|
|
ASX - By Stock
|
AN1 |
Re:
Company Research
|
|
quattro1
|
48 |
16K |
22 |
24/01/17 |
24/01/17 |
ASX - By Stock
|
48
|
16K
|
22
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Appendix 4C
|
|
quattro1
|
10 |
4.0K |
4 |
24/01/17 |
24/01/17 |
ASX - By Stock
|
10
|
4.0K
|
4
|
|
ASX - By Stock
|
AN1 |
Re:
Company Research
|
|
quattro1
|
48 |
16K |
15 |
11/12/16 |
11/12/16 |
ASX - By Stock
|
48
|
16K
|
15
|
|
ASX - By Stock
|
AN1 |
Re:
PEB: Positive Results in Kaiser Permanente User Programme
|
|
quattro1
|
22 |
7.6K |
18 |
09/12/16 |
09/12/16 |
ASX - By Stock
|
22
|
7.6K
|
18
|
|
ASX - By Stock
|
AN1 |
Re:
PEB: Positive Results in Kaiser Permanente User Programme
|
|
quattro1
|
22 |
7.6K |
16 |
24/11/16 |
24/11/16 |
ASX - By Stock
|
22
|
7.6K
|
16
|
|
ASX - By Stock
|
SNT |
A target for big pharma
|
|
quattro1
|
0 |
795 |
3 |
24/11/16 |
24/11/16 |
ASX - By Stock
|
0
|
795
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor Briefing - Presentation
|
|
quattro1
|
26 |
9.8K |
3 |
23/11/16 |
23/11/16 |
ASX - By Stock
|
26
|
9.8K
|
3
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor Briefing - Presentation
|
|
quattro1
|
26 |
9.8K |
1 |
23/11/16 |
23/11/16 |
ASX - By Stock
|
26
|
9.8K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: AGM Presentation by CEO
|
|
quattro1
|
63 |
17K |
16 |
21/11/16 |
21/11/16 |
ASX - By Stock
|
63
|
17K
|
16
|
|
ASX - By Stock
|
AN1 |
Re:
The US Deal
|
|
quattro1
|
106 |
33K |
0 |
16/11/16 |
16/11/16 |
ASX - By Stock
|
106
|
33K
|
0
|
|
ASX - By Stock
|
AN1 |
Re:
The US Deal
|
|
quattro1
|
106 |
33K |
25 |
16/11/16 |
16/11/16 |
ASX - By Stock
|
106
|
33K
|
25
|
|
ASX - By Stock
|
CYP |
Re:
What is Cynata’s Cymerus™ Technology
|
|
quattro1
|
4 |
1.5K |
5 |
10/11/16 |
10/11/16 |
ASX - By Stock
|
4
|
1.5K
|
5
|
|
ASX - By Stock
|
AN1 |
Re:
New evolis for men formulation
|
|
quattro1
|
11 |
7.1K |
13 |
03/11/16 |
03/11/16 |
ASX - By Stock
|
11
|
7.1K
|
13
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Quarterly Shareholder Update - September 2016-PXS.AX
|
|
quattro1
|
1 |
892 |
4 |
28/10/16 |
28/10/16 |
ASX - By Stock
|
1
|
892
|
4
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Change of Director's Interest Notice - Halasz-CDY.AX
|
|
quattro1
|
1 |
1.0K |
14 |
18/10/16 |
18/10/16 |
ASX - By Stock
|
1
|
1.0K
|
14
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Cellmid Records Highest Ever Quarterly Sales for Evolis-CDY.AX
|
|
quattro1
|
50 |
14K |
12 |
11/10/16 |
11/10/16 |
ASX - By Stock
|
50
|
14K
|
12
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Midkine Antibodies Show Anti-Tumor Activity In Brain Cancer-CDY.AX
|
|
quattro1
|
63 |
19K |
18 |
05/10/16 |
05/10/16 |
ASX - By Stock
|
63
|
19K
|
18
|
|
ASX - By Stock
|
AN1 |
Re:
The Next Investor
|
|
quattro1
|
364 |
102K |
17 |
14/09/16 |
14/09/16 |
ASX - By Stock
|
364
|
102K
|
17
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Corporate Presentation-CYP.AX
|
|
quattro1
|
55 |
11K |
10 |
07/09/16 |
07/09/16 |
ASX - By Stock
|
55
|
11K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation - 6 September 2016-PXS.AX
|
|
quattro1
|
7 |
3.0K |
6 |
06/09/16 |
06/09/16 |
ASX - By Stock
|
7
|
3.0K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: CYP & FUJIFILM Sign Non-Binding Terms Sheet-CYP.AX
|
|
quattro1
|
106 |
25K |
6 |
05/09/16 |
05/09/16 |
ASX - By Stock
|
106
|
25K
|
6
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Trading Halt-CYP.AX
|
|
quattro1
|
1 |
845 |
3 |
02/09/16 |
02/09/16 |
ASX - By Stock
|
1
|
845
|
3
|
|
ASX - By Stock
|
AN1 |
Re:
Is it time to call an EGM?
|
|
quattro1
|
97 |
23K |
2 |
31/08/16 |
31/08/16 |
ASX - By Stock
|
97
|
23K
|
2
|
|
ASX - By Stock
|
AN1 |
Re:
Is it time to call an EGM?
|
|
quattro1
|
97 |
23K |
1 |
31/08/16 |
31/08/16 |
ASX - By Stock
|
97
|
23K
|
1
|
|
ASX - By Stock
|
AN1 |
Re:
Is it time to call an EGM?
|
|
quattro1
|
97 |
23K |
1 |
31/08/16 |
31/08/16 |
ASX - By Stock
|
97
|
23K
|
1
|
|
ASX - By Stock
|
AN1 |
Is it time to call an EGM?
|
|
quattro1
|
97 |
23K |
3 |
31/08/16 |
31/08/16 |
ASX - By Stock
|
97
|
23K
|
3
|
|
ASX - By Stock
|
CYP |
Dr James Chong on Ch 9 News
|
|
quattro1
|
6 |
2.7K |
21 |
24/07/16 |
24/07/16 |
ASX - By Stock
|
6
|
2.7K
|
21
|
|